CHOH-01 is under clinical development by CHO Pharma and currently in Phase II for Marginal Zone B-cell Lymphoma. According to GlobalData, Phase II drugs for Marginal Zone B-cell Lymphoma have a 48% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how CHOH-01’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

CHOH-01 overview

CHOH-01 is under development for the treatment of follicular lymphoma, B-cell non-Hodgkin lymphoma, marginal zone lymphoma, small lymphocytic lymphoma, mantle cell lymphoma, diffuse large B-cell lymphoma, and primary mediastinal large B-cell lymphoma. It is administered through intravenous route. It is a glycol-engineered anti-CD20 antibody. It is a homogeneous antibody developed based on glycan engineering technology. The technology uses an enzymic reaction which modifies the mixture of sugar molecules on antibody drugs to make a single homogeneous glycoform. The drug candidate is developed based on CHOptimax technology.

CHO Pharma overview

CHO Pharma., is a biopharmaceutical company mainly focused on the development and commercialization of innovative products based on the proprietary glycan engineering technologies. The company is headquartered in Taiwan.

For a complete picture of CHOH-01’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.